However, approximately 20%~30% AML patients harbor an internal tandem duplication mutation of the FMS-like tyrosine kinase receptor (FLT3-ITD mutation) that was considered to be unfavorable. The gene discussed is FLT3; the disease is acute myeloid leukemia.